{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-008989","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.979930+00:00","generated_at":"2026-06-20T03:52:20.202582+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics closes $3.25M equity raise; existing warrants repriced to $1.55","bullets":["Raised ~$3.25M gross via registered direct offering of 1,940,299 shares and pre-funded warrants, plus private placement of 1,940,299 warrants.","Private placement warrants priced at $0.125 each, exercise price $1.55, 3-year term from initial exercise date; subject to registration.","Existing warrants (exp. Oct 2027) exercise price reduced from $3.30 to $1.55 effective Jan 27, 2023.","Executives, directors and 10%+ holders subject to 90-day lock-up from closing date (Jan 31, 2023).","Net proceeds to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-008989","json":"https://secwatch.observer/filing/0001104659-23-008989.json","markdown":"https://secwatch.observer/filing/0001104659-23-008989.md","text":"https://secwatch.observer/filing/0001104659-23-008989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/tm234660d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:52:20.202582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"062b3610726cfd83bc8ee061a35ad365f04763cf","claim":"AVENUE THERAPEUTICS, INC. entered into Registered Purchase Agreement with a single institutional accredited investor valued at approximately $3.0 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, Avenue Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Registered Purchase Agreement ”) with a single institutional accredited investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a single institutional accredited investor"},{"label":"Value","value":"approximately $3.0 million"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"},{"claim_id":"50d871736eedebaf133e319f16afe58ce2455b13","claim":"AVENUE THERAPEUTICS, INC. entered into Placement Agent Agreement with Aegis Capital Corp. (effective 2023-01-27).","evidence_excerpt":"Aegis Capital Corp. (“ Aegis ”) acted as the exclusive placement agent in connection with the Registered Offering and the Private Placement under a Placement Agent Agreement, dated as of January 27, 2023, between the Company and Aegis (the “ Placement Agent Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Aegis Capital Corp."},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"},{"claim_id":"8b12e5e286cff73e24ac21990655e945ebbb53c0","claim":"AVENUE THERAPEUTICS, INC. entered into Registration Rights Agreement with the investor (effective 2023-01-27).","evidence_excerpt":"In connection with the PIPE Purchase Agreement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investor"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"},{"claim_id":"9f5b01151ff4c52766cfcaf193c1facb9d3cf614","claim":"AVENUE THERAPEUTICS, INC. entered into PIPE Purchase Agreement with the same institutional accredited investor valued at approximately $0.24 million (effective 2023-01-27).","evidence_excerpt":"On January 27, 2023, the Company also entered into a Securities Purchase Agreement (the “ PIPE Purchase Agreement ”) with the same institutional accredited investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the same institutional accredited investor"},{"label":"Value","value":"approximately $0.24 million"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"},{"claim_id":"ac8ad8944ace809fa402676148962693429d254d","claim":"AVENUE THERAPEUTICS, INC. entered into Lock-Up Agreement with each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock (effective 2023-01-27).","evidence_excerpt":"Each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock entered into a lock-up agreement (the “ Lock-Up Agreement ”) pursuant to which they agreed not to sell or transfer any securities of the Company held by them for a period commencing on January 27, 2023 and ending ninety (90) days after the Effective Date (as defined in PIPE Purchase Agreement), subject to limited exceptions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923008989/0001104659-23-008989-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"each of the Company’s executive officers, directors and the holders of 10% or more of the Company’s outstanding shares of Common Stock"},{"label":"Effective","value":"2023-01-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}